Experimental Hematology & Oncology最新文献_第7页

Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities. 小细胞肺癌：新出现的亚型、信号通路和治疗弱点。

IF 9.4 1区医学

Experimental Hematology & Oncology Pub Date : 2024-08-05 DOI: 10.1186/s40164-024-00548-w

Jing Zhang, Xiaoping Zeng, Qiji Guo, Zhenxin Sheng, Yan Chen, Shiyue Wan, Lele Zhang, Peng Zhang

{"title":"Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities.","authors":"Jing Zhang, Xiaoping Zeng, Qiji Guo, Zhenxin Sheng, Yan Chen, Shiyue Wan, Lele Zhang, Peng Zhang","doi":"10.1186/s40164-024-00548-w","DOIUrl":"10.1186/s40164-024-00548-w","url":null,"abstract":"Small cell lung cancer (SCLC) is a recalcitrant cancer characterized by early metastasis, rapid tumor growth and poor prognosis. In recent decades, the epidemiology, initiation and mutation characteristics of SCLC, as well as abnormal signaling pathways contributing to its progression, have been widely studied. Despite extensive investigation, fewer drugs have been approved for SCLC. Recent advancements in multi-omics studies have revealed diverse classifications of SCLC that are featured by distinct characteristics and therapeutic vulnerabilities. With the accumulation of SCLC samples, different subtypes of SCLC and specific treatments for these subtypes were further explored. The identification of different molecular subtypes has opened up novel avenues for the treatment of SCLC; however, the inconsistent and uncertain classification of SCLC has hindered the translation from basic research to clinical applications. Therefore, a comprehensives review is essential to conclude these emerging subtypes and related drugs targeting specific therapeutic vulnerabilities within abnormal signaling pathways. In this current review, we summarized the epidemiology, risk factors, mutation characteristics of and classification, related molecular pathways and treatments for SCLC. We hope that this review will facilitate the translation of molecular subtyping of SCLC from theory to clinical application.","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"13 1","pages":"78"},"PeriodicalIF":9.4,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cell membrane patches transfer CAR molecules from a cellular depot to conventional T cells for constructing innovative fused-CAR-T cells without necessitating genetic modification. 细胞膜贴片可将细胞储库中的 CAR 分子转移到传统 T 细胞中，从而构建出创新的融合 CAR-T 细胞，而无需进行基因修饰。

IF 9.4 1区医学

Experimental Hematology & Oncology Pub Date : 2024-08-05 DOI: 10.1186/s40164-024-00545-z

Jing Hu, Luyi Zhong, Yiqiu Wang, Shiyi Hu, Lijiaqi Zhang, Qingchang Tian

引用次数: 0

1q jumping translocation as a biomarker in myeloid malignancy: frequently mutated genes associated with bad prognosis and low survival. 作为骨髓恶性肿瘤生物标志物的 1q 跳跃易位：与不良预后和低存活率相关的频繁突变基因。

IF 9.4 1区医学

Experimental Hematology & Oncology Pub Date : 2024-08-01 DOI: 10.1186/s40164-024-00541-3

Eitan Halper-Stromberg, Victoria Stinnett, Laura Morsberger, Aparna Pallavajjala, Mark J Levis, Amy E DeZern, Michelle Lei, Brian Phan, Rena R Xian, Christopher D Gocke, Guilin Tang, Ying S Zou

{"title":"1q jumping translocation as a biomarker in myeloid malignancy: frequently mutated genes associated with bad prognosis and low survival.","authors":"Eitan Halper-Stromberg, Victoria Stinnett, Laura Morsberger, Aparna Pallavajjala, Mark J Levis, Amy E DeZern, Michelle Lei, Brian Phan, Rena R Xian, Christopher D Gocke, Guilin Tang, Ying S Zou","doi":"10.1186/s40164-024-00541-3","DOIUrl":"10.1186/s40164-024-00541-3","url":null,"abstract":"1q jumping translocation (JT) is rare and its molecular profiles in myeloid malignancies are not well-known. This study evaluated gene mutations in 1q-JT cohorts (0.38%) from hematological malignant specimens that underwent genetic analysis at the Johns Hopkins Hospital (n = 11,908) and the MD Anderson Cancer Center. 1q-JT had frequent mutations in eleven genes, most of which are associated with worse prognosis. BCOR mutations significantly co-occurred with others. Patients tended to have mutations in DNA-repair, spliceosome, and epigenetic modification pathways, though genes utilized within each of these pathways were not randomly distributed. Multi-, albeit overlapping, pathway interruptions tended to manifest in mutations of two gene sets. One gene set consisted of SF3B1 (spliceosome) and TET2 (epigenetic modification), while the other consisted of STAG2 (DNA repair), SRSF2, U2AF (spliceosome), ASXL1, KMT2D (epigenetic modification), BCOR, and GATA2 (transcription factors). An \"intermediate\" JT-like rearrangement may represent an early sign of occurring 1q-JT. Treatments (hypomethylating agents) and unique structures of the short arms of acrocentric chromosomes may contribute to 1q-JT formation in myeloid malignancies. The median overall survival after identification of a JT was 10 months (95% confidence interval, 5-15 months). Our cohort represents the largest number of myeloid malignancies from multi-centers with before and after the 1q-JT event analyzed to date. Overall, this study identified specific molecular profiles that are associated with 1q-JT in myeloid malignancies. 1q-JT could serve as a poor prognosis biomarker in myeloid malignancies, which could be important in making well-informed clinical decisions and treatment strategies.","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"13 1","pages":"73"},"PeriodicalIF":9.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11295323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside. 肝细胞癌进展、转移和治疗过程中的免疫抑制性肿瘤微环境：从实验室到临床。

IF 9.4 1区医学

Experimental Hematology & Oncology Pub Date : 2024-08-01 DOI: 10.1186/s40164-024-00539-x

Yue Yin, Weibo Feng, Jie Chen, Xilang Chen, Guodong Wang, Shuai Wang, Xiao Xu, Yongzhan Nie, Daiming Fan, Kaichun Wu, Limin Xia

{"title":"Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside.","authors":"Yue Yin, Weibo Feng, Jie Chen, Xilang Chen, Guodong Wang, Shuai Wang, Xiao Xu, Yongzhan Nie, Daiming Fan, Kaichun Wu, Limin Xia","doi":"10.1186/s40164-024-00539-x","DOIUrl":"10.1186/s40164-024-00539-x","url":null,"abstract":"Hepatocellular carcinoma (HCC) is a highly heterogeneous malignancy with high incidence, recurrence, and metastasis rates. The emergence of immunotherapy has improved the treatment of advanced HCC, but problems such as drug resistance and immune-related adverse events still exist in clinical practice. The immunosuppressive tumor microenvironment (TME) of HCC restricts the efficacy of immunotherapy and is essential for HCC progression and metastasis. Therefore, it is necessary to elucidate the mechanisms behind immunosuppressive TME to develop and apply immunotherapy. This review systematically summarizes the pathogenesis of HCC, the formation of the highly heterogeneous TME, and the mechanisms by which the immunosuppressive TME accelerates HCC progression and metastasis. We also review the status of HCC immunotherapy and further discuss the existing challenges and potential therapeutic strategies targeting immunosuppressive TME. We hope to inspire optimizing and innovating immunotherapeutic strategies by comprehensively understanding the structure and function of immunosuppressive TME in HCC.","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"13 1","pages":"72"},"PeriodicalIF":9.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring whether ChatGPT-4 with image analysis capabilities can diagnose osteosarcoma from X-ray images 探索具有图像分析功能的 ChatGPT-4 能否通过 X 射线图像诊断骨肉瘤

IF 10.9 1区医学

Experimental Hematology & Oncology Pub Date : 2024-07-27 DOI: 10.1186/s40164-024-00537-z

Yi Ren, Yusheng Guo, Qingliu He, Zhixuan Cheng, Qiming Huang, Lian Yang

引用次数: 0

Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers. 最大限度提高 CAR-T 细胞免疫疗法疗效的输注和给药策略。

IF 9.4 1区医学

Experimental Hematology & Oncology Pub Date : 2024-07-26 DOI: 10.1186/s40164-024-00542-2

Xinyu Gu, Yalan Zhang, Weilin Zhou, Fengling Wang, Feiyang Yan, Haozhan Gao, Wei Wang

{"title":"Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers.","authors":"Xinyu Gu, Yalan Zhang, Weilin Zhou, Fengling Wang, Feiyang Yan, Haozhan Gao, Wei Wang","doi":"10.1186/s40164-024-00542-2","DOIUrl":"10.1186/s40164-024-00542-2","url":null,"abstract":"Chimeric antigen receptor (CAR) T-cell therapy has achieved substantial clinical outcomes for tumors, especially for hematological malignancies. However, extending the duration of remission, reduction of relapse for hematological malignancies and improvement of the anti-tumor efficacy for solid tumors are challenges for CAR-T cells immunotherapy. Besides the endeavors to enhance the functionality of CAR-T cell per se, optimization of the infusion and delivery strategies facilitates the breakthrough of the hurdles that limited the efficacy of this cancer immunotherapy. Here, we summarized the infusion and delivery strategies of CAR-T cell therapies under pre-clinical study, clinical trials and on-market status, through which the improvements of safety and efficacy for hematological and solid tumors were analyzed. Of note, novel infusion and delivery strategies, including local-regional infusion, biomaterials bearing the CAR-T cells and multiple infusion technique, overcome many limitations of CAR-T cell therapy. This review provides hints to determine infusion and delivery strategies of CAR-T cell cancer immunotherapy to maximize clinical benefits.","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"13 1","pages":"70"},"PeriodicalIF":9.4,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11282638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141765861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CAR-T cell combination therapies in hematologic malignancies. 血液恶性肿瘤中的 CAR-T 细胞联合疗法。

IF 9.4 1区医学

Experimental Hematology & Oncology Pub Date : 2024-07-18 DOI: 10.1186/s40164-024-00536-0

Delian Zhou, Xiaojian Zhu, Yi Xiao

引用次数: 0

Versatile function of NF-ĸB in inflammation and cancer. NF-ĸB 在炎症和癌症中的多种功能。

IF 9.4 1区医学

Experimental Hematology & Oncology Pub Date : 2024-07-16 DOI: 10.1186/s40164-024-00529-z

Qiang Ma, Shuai Hao, Weilong Hong, Vinay Tergaonkar, Gautam Sethi, Yu Tian, Chenyang Duan

{"title":"Versatile function of NF-ĸB in inflammation and cancer.","authors":"Qiang Ma, Shuai Hao, Weilong Hong, Vinay Tergaonkar, Gautam Sethi, Yu Tian, Chenyang Duan","doi":"10.1186/s40164-024-00529-z","DOIUrl":"10.1186/s40164-024-00529-z","url":null,"abstract":"Nuclear factor-kappaB (NF-ĸB) plays a crucial role in both innate and adaptive immune systems, significantly influencing various physiological processes such as cell proliferation, migration, differentiation, survival, and stemness. The function of NF-ĸB in cancer progression and response to chemotherapy has gained increasing attention. This review highlights the role of NF-ĸB in inflammation control, biological mechanisms, and therapeutic implications in cancer treatment. NF-ĸB is instrumental in altering the release of inflammatory factors such as TNF-α, IL-6, and IL-1β, which are key in the regulation of carcinogenesis. Specifically, in conditions including colitis, NF-ĸB upregulation can intensify inflammation, potentially leading to the development of colorectal cancer. Its pivotal role extends to regulating the tumor microenvironment, impacting components such as macrophages, fibroblasts, T cells, and natural killer cells. This regulation influences tumorigenesis and can dampen anti-tumor immune responses. Additionally, NF-ĸB modulates cell death mechanisms, notably by inhibiting apoptosis and ferroptosis. It also has a dual role in stimulating or suppressing autophagy in various cancers. Beyond these functions, NF-ĸB plays a role in controlling cancer stem cells, fostering angiogenesis, increasing metastatic potential through EMT induction, and reducing tumor cell sensitivity to chemotherapy and radiotherapy. Given its oncogenic capabilities, research has focused on natural products and small molecule compounds that can suppress NF-ĸB, offering promising avenues for cancer therapy.","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"13 1","pages":"68"},"PeriodicalIF":9.4,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-TIM3 chimeric antigen receptor-natural killer cells preferentially target primitive acute myeloid leukemia cells with minimal fratricide and exhaustion 抗 TIM3 嵌合抗原受体-自然杀伤细胞优先攻击原始急性髓性白血病细胞，自相残杀和衰竭现象极少

IF 10.9 1区医学

Experimental Hematology & Oncology Pub Date : 2024-07-11 DOI: 10.1186/s40164-024-00534-2

Phatchanat Klaihmon, Parinya Samart, Yon Rojanasakul, Surapol Issaragrisil, Sudjit Luanpitpong

{"title":"Anti-TIM3 chimeric antigen receptor-natural killer cells preferentially target primitive acute myeloid leukemia cells with minimal fratricide and exhaustion","authors":"Phatchanat Klaihmon, Parinya Samart, Yon Rojanasakul, Surapol Issaragrisil, Sudjit Luanpitpong","doi":"10.1186/s40164-024-00534-2","DOIUrl":"https://doi.org/10.1186/s40164-024-00534-2","url":null,"abstract":"Acute myeloid leukemia (AML) is an aggressive and genetically heterogeneous disease with poor clinical outcomes. Refractory AML is common, and relapse remains a major challenge, attributable to the presence of therapy-resistant leukemic stem cells (LSCs), which possess self-renewal and repopulating capability. Targeting LSCs is currently the most promising avenue for long-term management of AML. Likewise, chimeric antigen receptor (CAR)-natural killer (NK) cells have emerged as a promising alternative to CAR-T cells due to their intrinsic potential as off-the-shelf products and safer clinical profiles. Here, we introduced a third-generation CAR harboring TIM3 scFv, CD28, 4-1BB, and CD3ζ (CAR-TIM3) into human NK-92 cells, the only FDA-approved NK cell line for clinical trials. TIM3 was chosen as a target antigen owing to its differential expression in LSCs and normal hematopoietic stem/progenitor cells (HSPCs). The established CAR-TIM3 NK-92 cells effectively targeted TIM3 and displayed potent anti-tumor activity against various primitive AML cells, subsequently causing a reduction in leukemic clonogenic growth in vitro, while having minimal effects on HSPCs. CAR-TIM3 NK-92 cells significantly reduced leukemic burden in vivo and interestingly suppressed the engraftment of AML cells into the mouse liver and bone marrow. Surprisingly, we found that CAR-TIM3 NK-92 cells expressed relatively low surface TIM3, leading to a low fratricidal effect. As TIM3 and PD-1 are immune checkpoints involved in NK cell dysfunction, we further tested and found that CAR-TIM3 NK-92 cells are beneficial for alleviating NK cell exhaustion. Our findings highlight the potential application of CAR-TIM3 NK cells for cellular immunotherapy for TIM3+ AML.","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"31 1","pages":""},"PeriodicalIF":10.9,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141586266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fueling CARs: metabolic strategies to enhance CAR T-cell therapy 为 CAR 提供燃料：加强 CAR T 细胞疗法的代谢策略

IF 10.9 1区医学

Experimental Hematology & Oncology Pub Date : 2024-07-10 DOI: 10.1186/s40164-024-00535-1

Arne Van der Vreken, Karin Vanderkerken, Elke De Bruyne, Kim De Veirman, Karine Breckpot, Eline Menu

引用次数: 0